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The antifibrillatory and electrophysiologic actions of bepridil and butyl-methylenedioxyindene (BU-MDI), two 
intracellular calcium antagonists, were examined in anesthetized dogs. The administration of bepridil (1.0-10.0 mg/kg 
i.v.) significantly increased the electrical threshold for ventricular fibrillation determined during unobstructed coronary 
flow, and was associated with a significant decrease in ventricular excitability and a progressive depression in 
ventricular myocardial conduction. BU-MDI (3.0-30.0 mg/kg i.v.) did not significantly alter ventricular fibrillation 
thresholds during unobstructed coronary flow, nor did it significantly alter electrophysiologic properties such as 
ventricular excitability, conduction or refractoriness. The administration of either bepridil (10 mg/kg i.v.) or BU-MDI 
(30 mg/kg i.v.), however, resulted in significant increases in the ventricular fibrillation thresholds determined during 
transient myocardial ischemia, restoring the threshold values to corresponding non-ischemic levels. These results 
suggest that an inhibition of the action and/or availability of intracellular calcium may play a role in the 
antifibrillatory actions of BU-MDI and bepridil during transient ischemia. 
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1. Introduction 
Bepridil (CERM-1978) (B-(2-methylpropoxy)- 
methyl-N-phenyl-N-phenylmethyl)-l-pyrrolidine- 
ethanamine hydrochioride) and BU-MDI (2-n- 
butyl 3-dimethylamino-5,6-methylenedioxyindene 
hydrochloride) are structurally distinct compounds 
which have been characterized as 'intracellular 
calcium antagonists'. An inhibition of the action 
and /o r  availability of intracellular calcium has 
been proposed to contribute toward the smooth 
muscle relaxant and cardiodepressant actions of 
* To whom all correspondence should be addressed: Depart- 
ment of Pharmacology, M6322 Medical Science Building I, 
The University of Michigan Medical School, Ann Arbor, 
Michigan 48109, U.S.A. 
both bepridil (Vogel et al., 1979; Mras and 
Sperelakis, 1981) and BU-MDI (Rahwan et al., 
1977; Lynch and Rahwan, 1982; Heaslip and 
Rahwan, 1983). Pronounced cellular accumula- 
tions and slow, delayed (presumably intracellular) 
components of efflux have been demonstrated for 
bepridil (Mras and Sperelakis, 1982; Pang and 
Sperelakis, 1983) and BU-MDI (Lynch et al., 1983) 
in isolated cardiac and /o r  vascular smooth muscle 
preparations. Mitochondria and sarcoplasmic re- 
ticulum have been identified as potential sites of 
action for both bepridil (Younes et al., 1977, 1981; 
Younes and Constantin, 1980) and BU-MDI 
(Matlib et al., 1981; Lynch et al., 1983). 
In a variety of experimental animal models, 
BU-MDI (Piascik et al., 1979; Lynch et al., 1981, 
1982) and bepridil (Kane and Winslow, 1980; 
Marshall and Muir, 1981; Jackson et al., 1985; 
0014-2999/85/$03.30 © 1985 Elsevier Science Publishers B.V. 
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Torres et al., 1984) display a wide spectrum of 
antiarrhythmic activity. The purpose of the pre- 
sent investigation was to examine the antifibrilla- 
tory properties of these two compounds by de- 
termining their effects upon the ventricular fibril- 
lation threshold in the anesthetized dog during 
both unobstructed coronary flow and during tran- 
sient ischemia. The results of this investigation 
suggest that an inhibition of the action a n d / o r  
availability of calcium might play a role in the 
antifibrillatory actions of these two 'intracellular 
calcium antagonists'  during transient regional 
myocardial ischemia. 
2. Materials and methods 
2.1. Surgical preparation 
Male mongrel  dogs (12.0-15.0 kg) were 
anesthetized with intravenous sodium pentobar- 
bital, 30 mg/kg .  A cuffed endotracheal tube was 
inserted and the animals were ventilated with room 
air using a Harvard respirator. A cannula was 
inserted into the left common carotid artery to 
allow continuous monitoring of arterial pressure 
and a cannula was inserted into the left external 
jugular vein to facilitate drug administration. 
A left thoracotomy was performed in the fourth 
intercostal space and the heart was suspended in a 
pericardial cradle. The left anterior descending 
coronary artery was dissected free from the sur- 
rounding myocardium distal to the second diago- 
nal branch, and a loose ligature passed beneath 
the artery. An epicardial bipolar electrode (1 mm 
diameter silver electrodes embedded 3 mm apart 
in acrylic) was sutured to the right ventricular 
surface adjacent to the site of coronary artery 
isolation. This electrode was used for the delivery 
of trains of current pulses for the ventricular fibril- 
lation threshold determinations. A second epicar- 
dial bipolar electrode was sutured to the left 
ventricular surface in the distribution of the left 
circumflex coronary artery for the recording of 
local ventricular activation. A bipolar plunge elec- 
trode (25 gauge stainless steel, 5 mm in length, 2 
mm apart) was sutured into the left ventricular 
myocardium near the tip of the left atrial appen- 
dage for determination of excitation thresholds 
and refractory periods. Heart  rate was controlled 
with atrial pacing (4 ms duration pulses at twice 
diastolic threshold) via a bipolar clip electrode 
placed on the left atrial appendage. 
2.2. Measurement of electrophysiologic parameters 
and determination of ventricular fibrillation 
thresholds 
Electrocardiographic intervals and electrophysi- 
ologic parameters were determined immediately 
before ventricular fibrillation threshold determina- 
tions. Electrocardiographic intervals were mea- 
sured during sinus rhythm. A paced QT interval 
was determined during atrial pacing (3 Hz). 
Ventricular excitation thresholds, effective refrac- 
tory periods and activation times were determined 
during atrial pacing (3.5 Hz). The ventricular exci- 
tation threshold was defined as the minimum cur- 
rent required to produce a conducted ventricular 
beat at a stimulus duration of 4 ms delivered 250 
ms after the R-wave of the lead II electrocardio- 
gram. The ventricular effective refractory period 
was the longest R to stimulus interval at which a 
2 × threshold stimulus (4 ms duration) failed to 
produce a conducted ventricular beat. Ventricular 
activation time, the interval between the Q-wave 
of the lead II electrocardiogram and the largest 
deflection of the local ventricular electrogram (Q- 
EG), was measured on a Tektronix model 5111 
oscilloscope. 
Ventricular fibrillation thresholds were de- 
termined during atrial pacing (3.5 Hz). Trains of 4 
ms duration square-wave pulses (60 Hz, 200 ms 
duration) were delivered to the right ventricle be- 
ginning 50 ms after the peak of the R-wave. The 
output of a Grass S-88 stimulator, Grass SIU-5 
stimulus isolation unit and a Grass constant cur- 
rent unit was triggered from the R-wave of the 
lead II electrocardiogram using a Tektronix 565 
oscilloscope and a type 3A8 operational amplifier. 
Current intensity was increased in 1.0 mA incre- 
ments to 10 mA, then in 2.0 mA increments to 20 
mA, and in 5 mA increments until ventricular 
fibrillation occurred. Three trials were performed 
at each current intensity with 8- to 10-beat inter- 
vals between each trial. The lowest current inten- 
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sity producing ventricular fibrillation was defined 
as the ventricular fibrillation threshold. When 
fibrillation occurred, the heart was defibrillated 
immediately using a capacitor-discharge direct 
current defibrillator charged to 10 joules. 
2.3. Experimental protocol and drug administration 
Before drug or vehicle administration, two con- 
trol determinations of electrophysiologic parame- 
ters and ventricular fibrillation thresholds were 
made 15 min apart during unobstructed coronary 
flow. Thereafter, one control (pretreatment) de- 
termination of ventricular fibrillation threshold 
during a temporary occlusion of the left anterior 
descending coronary artery was made. This latter 
determination was started 2 min after occlusion of 
the artery and was completed by the 6th min of 
occlusion. After control pretreatment determina- 
tions had been made, three groups of six dogs each 
received bepridil (1.0, 3.0 and 10.0 mg/kg  i.v., 
cumulatively), BU-MDI (3.0, 10.0 and 30.0 mg/kg  
i.v., cumulatively) or matching volumes of vehicle 
for the aforementioned drug dosages (2.0, 6.0 and 
20.0 ml of 10% v / v  ethanol in distilled water, i.v., 
cumulatively). Each indicated treatment dosage or 
volume was achieved by a 10 min infusion and 
was followed 15 min later by redetermination of 
the electrophysiologic parameters and the ventricu- 
lar fibrillation threshold during unobstructed 
coronary flow. After the three groups of dogs had 
received a cumulative 20 ml of vehicle, 30 mg/kg  
BU-MDI or 10 mg/kg  bepridil, final determina- 
tions of the electrophysiologic parameters and the 
ventricular fibrillation threshold during unob- 
structed coronary flow were made. Fifteen minutes 
thereafter, a second (post-treatment) determina- 
tion of ventricular fibrillation threshold during 
acute coronary occlusion was made. Determina- 
tion of ventricular fibrillation threshold during 
transient regional ischemia was performed only 
twice in the protocol for each preparation (one 
determination pretreatment; the second post-treat- 
ment determination after full drug or vehicle ad- 
ministration) in order to avoid the potentially de- 
leterious effects of repeated coronary artery occlu- 
sions and reperfusions upon the electrophysiologic 
state of the preparation. Dosage ranges for be- 
pridil and BU-MDI in this study were based upon 
the activities of these compounds in previously 
reported antiarrhythmic evaluations (see Introduc- 
tion for references). 
2.4. Statistical analysis 
Data are expressed as means _+ S.E.M. For all 
parameters excluding fibrillation thresholds during 
coronary occlusion, the percentage change from 
the mean control response was computed for each 
dog. Following arcsine transformations, a one-way 
analysis of variance followed by a Dunnett 's test 
for multiple comparisons to one control (vehicle) 
group was used to detect significant differences 
between either drug-treated group and the 
volume-matched vehicle-treated group. Within 
each treatment group, a paired Student's t-test was 
used to compare pre- and post-treatment values of 
ventricular fibrillation threshold during coronary 
artery occlusion. P < 0.05 was the criterion of sig- 
nificance in all cases. 
3. Results 
3.1. Effect of vehicle administration on ventricular 
fibrillation threshold and electrophysiologic parame- 
ters 
The cumulative administration of up to 20 ml 
of vehicle (10% v / v  ethanol in distilled water) did 
not significantly alter ventricular fibrillation 
thresholds determined during unobstructed left 
anterior descending coronary flow. The ventricular 
fibrillation threshold values for cumulative volumes 
of vehicle are compared graphically to correspond- 
ing values for the bepridil-treated group in fig. 1. 
A slight but consistent decrease in the ventricular 
fibrillation threshold determined during tansient 
coronary occlusion was observed after cumulative 
vehicle treatment (fig. 2), indicating the develop- 
ment of an increased vulnerability toward ventric- 
ular fibrillation during transient ischemia over the 
course of the experiment. The pretreatment values 
for sinus heart rate, mean arterial pressure and 
electrophysiologic parameters for the vehicle treat- 
ment group did not differ significantly from the 
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Fig. 1. Effects of bepridil (striped bars) or corresponding 
volumes of vehicle (open bars) on the ventricular fibrillation 
threshold during unobstructed coronary flow. Depicted values 
are means  +S.E.M. with n = 6. (*) Indicates a significant 
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Fig. 2. Values for ventricular fibrillation threshold determined 
during transient regional ischemia before (pre) and after (post) 
the administration of vehicle (left panel), bepridil (center panel) 
or BU-MDI (right panel). The depicted values are means 
+ S.E.M. with n = 6. (*) Indicates a significant (P < 0.05) post 
vs. pre difference. 
pretreatment values observed for the bepridil (ta- 
ble 1) and BU-MDI treatment groups, nor did 
vehicle administration significantly alter these 
parameters. 
3.2. Effect of bepridil administration on ventricular 
fibrillation threshoM and electrophysiologic parame- 
ters 
The cumulative administration of bepridil, 1.0 
to 10.0 mg/kg  i.v., resulted in a significant eleva- 
tion in ventricular fibrillation thresholds de- 
TABLE 1 
The effects of  bepridil administration on electrophysiologic and hemodynamic parameters in pentobarbital-anesthetized, open-chest 
dogs. All values represent means + S.E.M. with n = 6. 
Control Bepridil ( m g / k g  i.v.) 
1.0 3.0 10.0 
Heart  rate (BPM) 149 + 6  146 5:10 137 + 8  124 + 9 a 
Mean arterial pressure 
(mmHg) 88 + 8  87 + 7 88 +5  91 + 5 
PR interval (ms) 116 +5  118 +5  123 +5  a 123 + 7 ~ 
QRS interval (ms) 61 + 2 62 5 : 1  61 5:1  62  5 : 1  
QTc interval (ms) 
(s) -1 /2  349 5:9 351 5:11 349 5:12 363 5:18 
Paced QT interval 
(ms) 210 + 5 224 5:11 226 5:10 238 5:14 
Ventricular activation 
t ime(ms)  24.1 5:4.0 27.4 5 : 2 . 1  27.9 5:2.3 30.6 5 : 2 . 6  
Ventricular excitation 
threshold (mA) 0.17 5:0.01 0.24 + 0.03 0.27 5:0.02 0.48 5 :0 .18  " 
Ventricular effective 
refractory period 
(ms) 159 5:8 163 + 7 167 5:8 158 5 : 4  
a P < 0 .05 .  
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termined during unobstructed coronary flow (fig. 
1). Dosages of 1.0 and 3.0 mg/kg bepridil pro- 
duced near equivalent 80-90% increases in the 
fibrillation threshold, while the cumulative 10 
mg/kg dose produced a 170% increase in fibrilla- 
tion threshold. The administration of 10 mg/kg 
bepridil also was associated with a significant 
elevation in the ventricular fibrillation threshold 
determined during transient regional myocardial 
ischemia (fig. 2). 
The electrophysiologic effects of bepridil ad- 
ministration are summarized in table 1. The 
cumulative administration of bepridil was associ- 
ated with increases in the ventricular excitation 
threshold (attaining statistical significance at 10 
mg/kg) as well as trends toward increasing 
ventricular activation times, QTc and paced QT 
intervals. A slight increase in ventricular refracto- 
riness was noted at 3 mg/kg bepridil. The ad- 
ministration of bepridil was associated with a slight 
but consistent increase in the PR interval (signifi- 
cant at 3.0 and 10.0 mg/kg) and a reduction in the 
sinus heart rate (significant at 10 mg/kg). 
3.3. Effect of BU-MDI on ventricular fibrillation 
threshold and electrophysiologic parameters 
The cumulative administration of BU-MDI, 3.0 
to 30.0 mg/kg i.v., resulted in only slight and 
insignificant alterations in the ventricular fibrilla- 
tion threshold determined during unobstructed 
coronary flow. The cumulative administration of 
30.0 mg/kg BU-MDI, however, resulted in a con- 
sistent and significant elevation in the ventricular 
fibrillation threshold determined during transient 
regional myocardial ischemia (fig. 2). BU-MDI 
administration did not significantly alter sinus 
heart rate, electrocardiographic intervals or elec- 
trophysiologic parameters determined during un- 
obstructed coronary flow. 
4. Discussion 
4.1. Ventricular fibrillation threshold determinations 
during unobstructed coronary flow - effects of be- 
pridil and BU-MD1 administration 
In the present evaluation, the administration of 
bepridil (1.0-10.0 mg/kg i.v.) significantly in- 
creased the electrical threshold for ventricular 
fibrillation determined during unobstructed 
coronary flow. A concomitant decrease in ventric- 
ular myocardial excitability (increased excitation 
thresholds) and a progressive depression in 
ventricular myocardial conduction (increased 
ventricular activation times) accompanied the ad- 
ministration of bepridil. These latter electrophysio- 
logic effects are suggestive of the actions of class I 
antiarrhythmic agents, inhibitors of fast channel 
sodium entry during myocardial cell depolariza- 
tion (Zipes, 1984). The antifibrillatory actions of 
bepridil in this setting may be due, at least in part, 
to these electrophysiological effects. In vitro be- 
pridil has been demonstrated to reduce the inten- 
sity of the fast inward sodium current in sheep 
Purkinje fibers (5 x 10 -6  to  2 X 10 -5 M bepridil) 
and in guinea pig ventricular muscle (2-8 × 10 -5 
M bepridil), suggesting that the compound dis- 
plays class I electrophysiologic effects at the cellu- 
lar level (Kane and Winslow, 1980). 
The administration of BU-MDI (3.0-30.0 mg/kg 
i.v.) did not significantly alter the ventricular 
fibrillation threshold determined during unob- 
structed coronary flow. In this dosage range, BU- 
MDI produced only a slight and insignificant in- 
crease in the ventricular excitation threshold and 
was associated with a slight progressive decrease in 
ventricular activation times (i.e. a slight enhance- 
ment in myocardial conduction). 
4.2. Ventricular fibrillation threshold determinations 
during transient ischemia - effects of bepridil and 
B U-MD1 administration 
It is well established that transient myocardial 
ischemia increases the degree of dispersion in re- 
covery of ventricular myocardium, and that this 
increased electrophysiologic inhomogeneity is re- 
flected in a decrease in ventricular fibrillation 
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threshold (Han, 1969; Axelrod et al., 1975). 
Accordingly, in the present study, the control pre- 
treatment values for the ventricular fibrillation 
threshold determined during a transient occlusion 
of the left anterior descending coronary artery 
were consistently and significantly less than corre- 
sponding pretreatment threshold values de- 
termined during unobstructed coronary flow, indi- 
cating an increased electrophysiologic instability 
during ischemia. A consistent and significant de- 
crease in the value for ventricular fibrillation 
threshold determined during transient ischemia was 
observed after cumulative vehicle administration. 
This increased vulnerability toward ventricular 
fibrillation during ischemia observed in the control 
group may well reflect metabolic alterations in the 
preparations during the course of the protocol 
(Moore and Spear, 1975). Despite this enhanced 
vulnerability toward ventricular fibrillation during 
transient ischemia, the administration of either 
bepridil (10 mg/kg i.v.) or BU-MDI (30 mg/kg 
i.v.) resulted in a significant increase in ventricular 
fibrillation threshold (compared to the appropriate 
pre-drug value) during coronary occlusion. For 
both bepridil and BU-MDI, post-treatment 
ventricular fibrillation thresholds determined dur- 
ing transient ischemia did not differ significantly 
from corresponding predrug values determined 
during unobstructed coronary flow. 
The ability of BU-MDI to significantly elevate 
the ventricular fibrillation threshold in the ischemic 
state at a dose that significantly altered neither 
fibrillation thresholds in the non-ischemic state 
nor electrophysiologic properties such as ventricu- 
lar excitability, conduction or refractoriness raises 
the possibility that the ability of BU-MDI to alter 
the availability and/or  action of cytosolic calcium 
may underlie its antifibrillatory activity during 
transient ischemia. Likewise, the ability of bepridil 
to modulate cytosolic calcium might also contrib- 
ute toward the elevation in the ventricular fibrilla- 
tion threshold during transient ischemia in the 
presence of the drug. It certainly may not be 
precluded that other pharmacologic actions of 
these compounds, most particularly the actions of 
bepridil upon myocardial conduction and excita- 
bility, might underlie, in part, the antifibrillatory 
actions of these compounds during transient 
ischemia. Taken together, however, the foregoing 
results suggest the possibility that an inhibition of 
the action and/or  availability of intracellular 
calcium may play a role in the antifibrillatory 
actions of BU-MDI and of bepridil during tran- 
sient myocardial ischemia. Such a protective, anti- 
fibrillatory action of these 'intracellular calcium 
antagonists' during ischemia is fully consistent with 
the concept that intracellular calcium accumula- 
tion plays a primary role in the pathophysiology of 
myocardial ischemia (Trump et al., 1982; Nayler, 
1983). 
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